Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- R&D NEWS IN BRIEF
September 1, 2008
- Takeda to Become One of the Top-Three Oncology Companies: President Hasegawa
September 1, 2008
- Kyorin Obtains Encouraging PIIa Results with KRP-104
September 1, 2008
- Nisshin Seifun Withdraws from Ethical Drug Business by Selling Joint Venture to Kyorin
September 1, 2008
- AZ, SCC to Help Elimination of Drug Lag through Joint Research
September 1, 2008
- Prasugrel Inhibits Recurrence of CV Events More Effectively than Clopidogrel
September 1, 2008
- REGULATORY NEWS IN BRIEF
September 1, 2008
- MCHC Aims at Developing Comprehensive Healthcare Businesses: President Kobayashi
September 1, 2008
- Largest Number of Drugs Unavailable in Japan among 11 Countries: OPIR Survey
September 1, 2008
- Depression Linked to Changes in Cerebral Blood Flow
September 1, 2008
- Criteria for Use of Thalidomide Announced
September 1, 2008
- SAS Present in 1 out of 3 Type 2 Diabetics
September 1, 2008
- Toho Becomes a Major Shareholder of a Generic Maker
September 1, 2008
- Accused Surgeon Found Not Guilty by District Court
September 1, 2008
- Korosho to Demand Budget to Increase PMDA Staff Responsible for Safety Measures by 100
September 1, 2008
- JCR to Request Application for Higher Doses of MTX Based on Public Knowledge
September 1, 2008
- Yamato HD to Introduce New Direct Delivery System for Generics
September 1, 2008
- Doctors' Awareness Needs to Be Renovated to Popularize Biologics for RA
September 1, 2008
- Statistics／Drug Sales Up 0.7% in June: Crecon R&C
September 1, 2008
- No Evidence for Giving Priority to Iressa: CDFS
September 1, 2008
ページ
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Adeno-associated virus (AAV) gene therapies have long been viewed as carrying only a minimal risk of insertional mutagenesis — a…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…